Shanghai Chia Tai Tianqing Pharmaceutical Technology Development
CompanyChina
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development develops 3 assets, the furthest in phase 2 (Kylo-0603 in metabolic dysfunction-associated steatoic liver disease). Mostly small molecule and antibody; based in China.
- 3
- Assets
- Furthest stage
- Phase 2
- 7
- Trials
- 2
- Signals
Pipeline
3Selectively activates hepatic thyroid hormone receptor beta to regulate lipid metabolism and reduce liver fat, inflammation, and fibrosis.
Phase 2, Small molecule, metabolic dysfunction-associated steatoic liver disease
Monoclonal antibody targeting inflammatory pathways in COPD
Phase 2, Antibody, chronic obstructive pulmonary disease
Injectable therapeutic agent for overweight and obesity
Phase 1, Peptide, obesity overweight
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Trials7
- Signals2
- Similar companies6